164 related articles for article (PubMed ID: 26039213)
1. Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.
Schlegel P; Feuchtinger T; Nitschke-Gérard C; Seidel UJ; Lang AM; Kyzirakos C; Teltschik HM; Ebinger M; Schumm M; Koscielniak E; Handgretinger R; Lang P
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S72-6. PubMed ID: 26039213
[TBL] [Abstract][Full Text] [Related]
2. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects.
Lang P; Pfeiffer M; Müller I; Schumm M; Ebinger M; Koscielniak E; Feuchtinger T; Föll J; Martin D; Handgretinger R
Klin Padiatr; 2006; 218(6):321-6. PubMed ID: 17080334
[TBL] [Abstract][Full Text] [Related]
4. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
[TBL] [Abstract][Full Text] [Related]
5. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
Boyiadzis M; Memon S; Carson J; Allen K; Szczepanski MJ; Vance BA; Dean R; Bishop MR; Gress RE; Hakim FT
Biol Blood Marrow Transplant; 2008 Mar; 14(3):290-300. PubMed ID: 18275895
[TBL] [Abstract][Full Text] [Related]
8. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
10. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
[TBL] [Abstract][Full Text] [Related]
11. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
Ozkaynak MF; Matthay K; Cairo M; Harris RE; Feig S; Reynolds CP; Buckley J; Villablanca JG; Seeger RC
J Clin Oncol; 1998 Mar; 16(3):937-44. PubMed ID: 9508176
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2007 Jun; 13(6):734-44. PubMed ID: 17531784
[TBL] [Abstract][Full Text] [Related]
13. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
[TBL] [Abstract][Full Text] [Related]
14. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
15. [Alloreactive NK cells enhance the effect of donor lymphocyte infusion in the management of relapsed lung cancer after haploidentical hematopoietic stem cell transplantation].
Yu JP; Sun HY; Li H; Cao S; Xin N; Ren XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):164-9. PubMed ID: 19236771
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
17. Loss of mismatched HLA in myeloid/NK cell precursor acute leukemia relapse after T cell-replete haploidentical hematopoietic stem cell transplantation.
Kobayashi S; Kikuta A; Ito M; Sano H; Mochizuki K; Akaihata M; Waragai T; Ohara Y; Ogawa C; Ono S; Ohto H; Hosoya M
Pediatr Blood Cancer; 2014 Oct; 61(10):1880-2. PubMed ID: 24464971
[TBL] [Abstract][Full Text] [Related]
18. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
20. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]